Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2025 | $23.50 | Neutral | Redburn Atlantic |
| 3/24/2025 | $25.00 | In-line | Evercore ISI |
| 1/6/2025 | $21.00 → $26.00 | Neutral → Overweight | Piper Sandler |
| 12/12/2024 | $25.00 → $24.00 | Buy → Hold | Deutsche Bank |
| 9/24/2024 | $27.00 | Buy | Jefferies |
| 9/24/2024 | $24.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 5/28/2024 | $21.00 | Neutral | Citigroup |
| 4/11/2024 | $18.00 | Underperform | Bernstein |
4 - Kenvue Inc. (0001944048) (Issuer)
3 - Kenvue Inc. (0001944048) (Issuer)
3 - Kenvue Inc. (0001944048) (Issuer)
Appoints Current Kenvue Director and Proven CPG and Technology Company Leader, Kirk Perry, as Interim CEO, Effective Immediately Announces Ongoing Review of Strategic Alternatives Reports Select Preliminary Second Quarter 2025 Financial Results Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors is implementing a set of actions to enable the Company to unlock shareholder value and reach its full potential. The Board has made a Chief Executive Officer transition and is advancing an ongoing comprehensive review of strategic alternatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714520711/en/Kirk
Kenvue Inc. (NYSE:KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation. "Being named to the Fortune 500 list marks a significant milestone for Kenvue," said Thibaut Mongon, Chief Executive Officer. "Recognitions like this validate the hard work and dedication of our K
Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO Succeeds Paul Ruh, Effective May 12, 2025 Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition. Mr. Banati is a 30-year consumer products company finance and operation
Net Sales (4.0)%; Organic Sales1 (4.2)% Diluted EPS was $0.22; Adjusted Diluted EPS1 was $0.29 Continues to Advance Ongoing Review of Strategic Alternatives, While Taking Actions to Accelerate Profitable Growth Under the New Executive Team Revises Outlook for FY'25 Kenvue Inc. (NYSE:KVUE) today announced financial results for the second quarter ended June 29, 2025. "Kenvue has a strong portfolio of world-class, category-defining brands. We are actively focused on improving execution and performance, while advancing the comprehensive strategic alternatives review, to deliver our inherent value," said Kirk Perry, Interim Chief Executive Officer. "I'm thrilled to take on this ne
Kenvue Inc. (NYSE:KVUE) today announced its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock, which represents a 1.2 percent increase compared to the prior quarterly dividend. The quarterly dividend is payable on August 27, 2025, to shareholders of record as of the close of business on August 13, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the ex
Kenvue Inc. (NYSE:KVUE) will announce its second quarter 2025 financial results before the market opens on August 7, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
Redburn Atlantic initiated coverage of Kenvue with a rating of Neutral and set a new price target of $23.50
Evercore ISI initiated coverage of Kenvue with a rating of In-line and set a new price target of $25.00
Piper Sandler upgraded Kenvue from Neutral to Overweight and set a new price target of $26.00 from $21.00 previously
SCHEDULE 13G/A - Kenvue Inc. (0001944048) (Subject)
10-Q - Kenvue Inc. (0001944048) (Filer)
8-K - Kenvue Inc. (0001944048) (Filer)
Net Sales (4.0)%; Organic Sales1 (4.2)% Diluted EPS was $0.22; Adjusted Diluted EPS1 was $0.29 Continues to Advance Ongoing Review of Strategic Alternatives, While Taking Actions to Accelerate Profitable Growth Under the New Executive Team Revises Outlook for FY'25 Kenvue Inc. (NYSE:KVUE) today announced financial results for the second quarter ended June 29, 2025. "Kenvue has a strong portfolio of world-class, category-defining brands. We are actively focused on improving execution and performance, while advancing the comprehensive strategic alternatives review, to deliver our inherent value," said Kirk Perry, Interim Chief Executive Officer. "I'm thrilled to take on this ne
Kenvue Inc. (NYSE:KVUE) today announced its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock, which represents a 1.2 percent increase compared to the prior quarterly dividend. The quarterly dividend is payable on August 27, 2025, to shareholders of record as of the close of business on August 13, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the ex
Kenvue Inc. (NYSE:KVUE) will announce its second quarter 2025 financial results before the market opens on August 7, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's